CsA can inhibit the transcription of IL-17mRNA and the secretion of IL-17 from CD4+T lymphocytes in patients with RA, thereby reducing the inflammatory response to RA and significantly enhancing bone tissue destruction (56). Here, IL17A is linked to rheumatoid arthritis.